Clinical Trial: Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome

Study Status: Available
Recruit Status: Available
Study Type: Expanded Access

Official Title: Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)

Brief Summary: To learn more about the effect of 3, 4-Diaminopyridine (3,4-DAP) on patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS).

Detailed Summary:
Sponsor: University of Colorado, Denver

Current Primary Outcome:

Original Primary Outcome: Effectiveness in treating weakness associated with Lambert-Eaton Myasthenic Syndrome(LEMS) based on the Medical Research Council (MRC) 12 point quantitative scale. [ Time Frame: 1 Year ]

Treatment period for each subject depends on the availability of 3,4 -DAP through the Expanded Access program from Jacobus Pharmaceutical Company,Inc.


Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Colorado, Denver

Dates:
Date Received: March 22, 2013
Date Started: July 2004
Date Completion: March 2050
Last Updated: December 21, 2016
Last Verified: December 2016